



P R O V I D E R B U L L E T I N

B T 2 0 0 5 0 3

F E B R U A R Y 2 5 , 2 0 0 5

To: All Pharmacy Providers and Prescribing Practitioners

Subject: Changes to the Preferred Drug List

Note: The information referenced below is not directed to those providers rendering services in the risk-based managed care (RBMC) delivery system.

Overview

This bulletin announces the Preferred Drug List (PDL) decisions made at the February 18, 2005, Drug Utilization Review (DUR) Board meeting. These decisions were based on the recommendations from the Therapeutics Committee meeting held on February 4, 2005. Please refer to Table 1 for a summary of these changes. **These changes are effective March 22, 2005.**

The PDL can be accessed at www.indianapbm.com. Notice of the DUR Board meetings and agendas are posted on the Family and Social Services Administration (FSSA) Web site at <http://www.state.in.us/fssa/> under the tab titled **Calendar**. Information about the Therapeutics Committee and the PDL is available at <http://www.indianapbm.com>.

Please direct prior authorization requests and questions about the PDL to the ACS Clinical Call Center at 1-866-879-0106. Questions about this bulletin should be directed to the ACS Pharmacy Services Helpdesk at 1-866-645-8344.

Table 1 – Approved Changes to the PDL Effective March 22, 2005

Drug Class	Drug	PDL Status
Non-Sedating Antihistamines	Clarinet Syrup	Preferred – Limited to patients 6 years and younger with a quantity limit of 10 ml/day
Fluoroquinolones	Levaquin Solution	Preferred – Limited to 14-day supply
Beta Blockers	Coreg	Preferred – Change current step-edit from requiring patient to be on a diuretic to requiring patient to be on an ACE or ARB.
Calcium Channel Blocker with HMG CoA Reductase Inhibitor	Caduet	Preferred – Add new strengths